BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 hours ago
- Business Wire
Avnet to Report Fourth Quarter and Fiscal Year 2025 Earnings on August 6 and to Hold Annual Shareholder Meeting on November 21
PHOENIX--(BUSINESS WIRE)-- Avnet (Nasdaq: AVT), a global technology solutions company, today announced it will report financial results for the fourth quarter and fiscal year 2025 on August 6, 2025 before the market opens. Following the earnings release, Avnet's Chief Executive Officer Phil Gallagher and Chief Financial Officer Ken Jacobson will host a webcast and conference call at 9:00 a.m. PT / Noon ET to discuss the financial results and provide a corporate update. Avnet's Board has also scheduled the Annual Meeting of Shareholders for Friday, November 21, 2025 at 8:00 a.m. Phoenix, Arizona time. The meeting will be held at Avnet's Corporate Headquarters located at: 2211 South 47th Street, Phoenix, Arizona 85034. The record date for determining the common shareholders entitled to vote at the meeting has been set at the close of business on September 22, 2025. Earnings Conference Call and Webcast Details To participate in the live call, dial 877-407-8112 or 201-689-8840. The live webcast along with slides can be accessed via Avnet's Investor Relations web page at An audio replay of the webcast will be available after the completion of the call and archived on the Avnet website for one year. About Avnet As a leading global technology distributor and solutions provider, Avnet has served customers' evolving needs for more than a century. Through regional and specialized businesses around the world, we support customers and suppliers at every stage of the product lifecycle. We help companies adapt to change and accelerate the design and supply stages of product development. With a unique viewpoint from the center of the technology value chain, Avnet is a trusted partner that solves complex design and supply chain issues so customers can realize revenue faster. Learn more about Avnet at (AVT_IR)
Medscape
10 hours ago
- Medscape
Novel Agents Transform Double-Refractory CLL Care
TOPLINE: Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic lymphocytic leukemia (CLL). Novel BTK-directed therapies and T-cell-engaging bispecific antibodies demonstrate promising responses in early-phase trials for pretreated CLL. METHODOLOGY: Researchers conducted a comprehensive review of mechanisms responsible for resistance to covalent BTK inhibitors and B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax in CLL. Analysis included evaluation of recent evidence supporting novel and emerging agent classes, including noncovalent BTK inhibitors, CAR T-cell therapy, and T-cell-engaging bispecific antibodies. Investigators examined treatment strategies incorporating these therapies in patients with double-refractory disease, considering variability in access to novel therapies and clinical trials. TAKEAWAY: Pirtobrutinib demonstrated an overall response rate of 72% in patients with chronic lymphocytic leukemia, with a median progression-free survival of 14 months compared with 8.7 months for control therapies. Lisocabtagene maraleucel achieved an overall response rate of 44% in double-refractory patients, with grade ≥ 3 cytokine release syndrome occurring in 8% and neurologic events in 19% of patients. BTK degraders showed promising early results, with BGB-16673 achieving responses in heavily pretreated patients, most of whom (92%) were exposed to covalent BTK inhibitors and BCL-2i. Epcoritamab demonstrated an overall response rate of 53% in double-exposed patients, with a complete response rate of 37% and undetectable measurable residual disease in two thirds of responders. IN PRACTICE: 'Within the current regulatory environment, either ncBTKi [noncovalent BTK inhibitor] or CAR T-cell therapy should be considered as first-line management for double-refractory disease, with the choice individualized based on disease stage, BTK mutational status, toxicity from prior therapies, performance status, comorbidities, and geographic and financial constraints,' the authors of the study wrote. SOURCE: This study was led by Brian T. Grainger of Sir Charles Gairdner Hospital in Nedlands, Australia. It was published online in Blood. LIMITATIONS: The literature describing CLL in the post-covalent BTK inhibitor and BCL-2i setting varies in criteria used to identify double-refractory patients, complicating assessment of disease prevalence and prognosis. Additionally, there were limited prospective data for outcomes following one class of targeted agent after disease progression on the other. DISCLOSURES: Philip A. Thompson disclosed relationships with AbbVie, Ascentage Pharma, AstraZeneca, BeiGene, Genentech, Genmab, Janssen Pharmaceuticals, Eli Lilly and Company, Merck, Adaptive Biotechnologies, Roche, and Sana Biotechnology. Additional disclosures were noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
a day ago
- Yahoo
Roots Announces Results of Voting at Fiscal 2024 Annual and Special Meeting of Shareholders and Changes to Board of Directors
TORONTO, July 22, 2025--(BUSINESS WIRE)--Roots ("Roots," "Roots Canada" or the "Company") (TSX: ROOT), a premium-outdoor lifestyle brand, today announced the results of voting at its Fiscal 2024 Annual and Special Meeting of Shareholders held today (the "Meeting"). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual and Special Meeting of Shareholders and Management Information Circular of Roots dated June 6, 2025. The total number of shares represented at the Meeting was 32,924,989, representing approximately 82% of Roots' outstanding shares entitled to be voted. Election of Directors All of the nominees listed in the Management Information Circular prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented in person or by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed. The following represents the votes received with regard to such matter: Nominee Votes For % Votes For Votes Against % Votes Against Phil Bacal 32,880,672 99.87% 43,987 0.13% Scott Cameron 32,882,972 99.87% 41,687 0.13% Mary Ann Curran 32,887,789 99.89% 36,870 0.11% Gregory David 32,887,732 99.89% 36,927 0.11% Edward H. Kernaghan 32,893,372 99.90% 31,287 0.10% Dale H. Lastman, C.M., O. Ont. 32,883,982 99.88% 40,677 0.12% Dexter Peart 32,886,772 99.88% 37,887 0.12% Meghan Roach 32,883,989 99.88% 40,670 0.12% Erol Uzumeri 32,867,677 99.83% 56,982 0.17% As previously disclosed, Richard Mavrinac and Joel Teitelbaum did not seek re-election at the Meeting. Meghan Roach, President and Chief Executive Officer of Roots, stated: "We look forward to welcoming Scott Cameron and Ed Kernaghan to the Roots Board of Directors. Scott's deep experience in Asia will be additive as we continue to explore global expansion, while Ed brings a strong background in capital markets and public company boards. I would also like to sincerely thank Joel Teitelbaum and Richard Mavrinac for their commitment and meaningful contributions to Roots over the years." Erol Uzumeri, Chairman of the Board, added: "We are excited to strengthen our Board with the appointments of Scott and Ed, whose complementary skills fit perfectly with our goals. Scott's international experience and Ed's governance expertise will bring valuable insights to our discussions as we work toward a promising future. On behalf of the Board, I am grateful to Joel and Richard for their thoughtful leadership and commitment throughout their tenure." Scott Cameron is a self-employed consultant advising and financing ventures in the consumer, apparel, and sports/athletics sectors. Between 2021-2022, he served as CEO of Hourglass Cosmetics, a cruelty-free luxury beauty brand. Prior to that, Mr. Cameron held several senior executive roles at Canada Goose from 2016-2021, including President of Asia-Pacific, President of Greater China, EVP of Stores and Ecommerce, and Chief Strategy and Business Development Officer. Before Canada Goose, Mr. Cameron was a Partner in the Consumer and Retail practice at McKinsey & Company, advising global brands on growth strategy, merchandising, international expansion, organization, and digital transformation. He holds an MBA from Harvard Business School, where he was a George Baker Scholar, and a Bachelor of Commerce (Honours) from Queen's University. Edward Kernaghan is currently President of Kernwood Limited and a partner at Kernaghan & Partners, positions he has held since October 2000 and January 2015, respectively. Mr. Kernaghan has over 15 years of experience in the financial services business. He held the position of Executive Vice-President at Kernaghan Securities, a firm he started along with his father, Ted Kernaghan, in 2001. Mr. Kernaghan also currently serves on a number of other public company boards, including Velan Inc., Exco Technologies Limited, Obsidian Energy Ltd. and Black Diamond Group Limited. Mr. Kernaghan is a graduate of the University of Toronto with a Master of Science in Theoretical Physics, and he has a Bachelor of Science, Honors degree from Queen's University. Appointment of Auditors KPMG LLP was reappointed as auditor of Roots and the directors were authorized to fix the auditor's remuneration by a resolution passed by a majority of the shareholders represented in person or by proxy at the Meeting. The following represents the votes received with regard to such matter: Votes For % Votes For Votes Withheld % Votes Withheld 32,905,219 99.94% 19,770 0.06% Approval of Amendment to Omnibus Equity Incentive Plan The adoption of the amendment to Roots' omnibus equity incentive plan was approved by a resolution passed by a majority of the shareholders present or represented by proxy at the Meeting. As a result, the total number of common shares of Roots available for issuance under the omnibus equity incentive plan has increased from 3,679,220 common shares to 4,084,703 common shares. The following represents the votes received with regard to such matter: Votes For % Votes For Votes Against % Votes Against 32,761,398 99.50% 163,261 0.50% About Roots Established in 1973, Roots is a global lifestyle brand. Starting from a small cabin in northern Canada, Roots has become a global brand with over 100 corporate retail stores in Canada, two stores in the United States, and an eCommerce platform, We have more than 100 partner-operated stores in Asia, and we also operate a dedicated Roots-branded storefront on in China. We design, market, and sell a broad selection of products in different departments, including women's, men's, children's, and gender-free apparel, leather goods, footwear, and accessories. Our products are built with uncompromising comfort, quality, and style that allows you to feel At Home With NatureTM. We offer products designed to meet life's everyday adventures and provide you with the versatility to live your life to the fullest. We also wholesale through business-to-business channels and license the brand to a select group of licensees selling products to major retailers. Roots Corporation is a Canadian corporation doing business as "Roots" and "Roots Canada". View source version on Contacts For further information: Roots Investor Relationsinvestors@ 1-844-762-2343
